|
Cell line
|
Basal CD26 expression (cpm/105 cells)
|
Drug treatment
|
|---|
| | |
5-FU
|
Cis
|
Vin
|
MTX
|
|---|
| | |
Maximal increase (% over control)
|
|
HT-29
|
1,300 ± 140
|
30 ± 5.8**
|
72 ± 26***
|
41 ± 10**
|
26 ± 6.4**
|
|
T84
|
780 ± 69
|
84 ± 14*
|
61 ± 42
|
78 ± 6.6
|
73 ± 42
|
|
HRT-18
|
370 ± 64
|
17 ± 9.1*
|
19 ± 9.1
|
23 ± 12
|
18 ± 9.4**
|
|
SW480
|
55 ± 15
|
96 ± 58*
|
90 ± 66
|
100 ± 59**
|
170 ± 150
|
|
SW620
|
26 ± 12
|
36 ± 31
|
28 ± 30
|
45 ± 43
|
53 ± 49
|
- The relative basal cell-surface protein expression for each cell line was summarized from 12–5 independent experiments. Cells were treated with drugs (5-FU, 5-fluorouracil [0.1 – 1,000 μg/mL]; Cis, cisplatin [0.001 – 10 μg/mL]; Vin, vinblastine [0.001 – 10 μg/mL]; MTX, methotrexate [0.1 – 1,000 μg/mL]) and cell surface expression of CD26 was determined by radioimmunobinding assay 48 h later. Maximal up-regulation of CD26 was recorded from 3–7 independent dose–response experiments for each drug and cell line. Data are shown as mean % increases ± SE for the moderate/high CD26-expressing cell lines, and mean numerical increases (cpm/105 cells) ± SE for the low expressers. *, significant increase due to drug, P < 0.05; **, P < 0.01; ***, P < 0.001, using paired t-test
